Why the study?
Whether circulating ANGPTL2 levels predict vital prognosis in younger-old, community-dwelling populations was previously unknown.
Do elevated plasma ANGPTL2 levels predict all-cause and cancer mortality in younger-old community-dwelling adults?
Population
714 randomly sampled participants plus 387 deceased cases aged 64 years at baseline
Comparison
Plasma ANGPTL2 concentrations
Design
Population-based prospective case-cohort study
Follow-up
Through 2015
Key result
Elevated plasma ANGPTL2 levels were associated with a >80% higher risk of all-cause mortality and a 100% higher risk of cancer mortality in community-dwelling adults aged 64 years.
Authors
Loading...
May signal higher mortality risk in younger-old adults; leaves open ANGPTL2's role in risk stratification pending validation.
Cohort (n=3,073)
Do elevated plasma ANGPTL2 levels predict all-cause and cancer mortality in younger-old community-dwelling adults?
Effect estimate: >80% and 100% higher risk
Elevated plasma ANGPTL2 levels are associated with significantly higher all-cause and cancer mortality in younger-old adults, suggesting its potential utility as a biomarker for aging-related risk.
Zhao et al. (2022) reported a cohort. Elevated plasma ANGPTL2 levels vs. Lower plasma ANGPTL2 levels was evaluated on All-cause and cancer mortality (>80% and 100% higher risk). Elevated plasma ANGPTL2 levels were associated with a >80% higher risk of all-cause mortality and a 100% higher risk of cancer mortality in community-dwelling adults aged 64 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: